APP Processing in Human Pluripotent Stem Cell-Derived Neurons Is Resistant to NSAID-Based γ-Secretase Modulation
Identifieur interne : 000260 ( Pmc/Corpus ); précédent : 000259; suivant : 000261APP Processing in Human Pluripotent Stem Cell-Derived Neurons Is Resistant to NSAID-Based γ-Secretase Modulation
Auteurs : Jerome Mertens ; Kathrin Stüber ; Patrick Wunderlich ; Julia Ladewig ; Jaideep C. Kesavan ; Rik Vandenberghe ; Mathieu Vandenbulcke ; Philip Van Damme ; Jochen Walter ; Oliver Brüstle ; Philipp KochSource :
- Stem Cell Reports [ 2213-6711 ] ; 2013.
Abstract
Increasing evidence suggests that elevated Aβ42 fractions in the brain cause Alzheimer’s disease (AD). Although γ-secretase modulators (GSMs), including a set of nonsteroidal anti-inflammatory drugs (NSAIDs), were found to lower Aβ42 in various model systems, NSAID-based GSMs proved to be surprisingly inefficient in human clinical trials. Reasoning that the nonhuman and nonneuronal cells typically used in pharmaceutical compound validation might not adequately reflect the drug responses of human neurons, we used human pluripotent stem cell-derived neurons from AD patients and unaffected donors to explore the efficacy of NSAID-based γ-secretase modulation. We found that pharmaceutically relevant concentrations of these GSMs that are clearly efficacious in conventional nonneuronal cell models fail to elicit any effect on Aβ42/Aß40 ratios in human neurons. Our work reveals resistance of human neurons to NSAID-based γ-secretase modulation, highlighting the need to validate compound efficacy directly in the human cell type affected by the respective disease.
Url:
DOI: 10.1016/j.stemcr.2013.10.011
PubMed: 24371804
PubMed Central: 3871388
Links to Exploration step
PMC:3871388Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">APP Processing in Human Pluripotent Stem Cell-Derived Neurons Is Resistant to NSAID-Based γ-Secretase Modulation</title><author><name sortKey="Mertens, Jerome" sort="Mertens, Jerome" uniqKey="Mertens J" first="Jerome" last="Mertens">Jerome Mertens</name><affiliation><nlm:aff id="aff1">Institute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Stuber, Kathrin" sort="Stuber, Kathrin" uniqKey="Stuber K" first="Kathrin" last="Stüber">Kathrin Stüber</name><affiliation><nlm:aff id="aff1">Institute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, 53127 Bonn, Germany</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">Life&Brain GmbH, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Wunderlich, Patrick" sort="Wunderlich, Patrick" uniqKey="Wunderlich P" first="Patrick" last="Wunderlich">Patrick Wunderlich</name><affiliation><nlm:aff id="aff3">Department of Neurology, University of Bonn, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Ladewig, Julia" sort="Ladewig, Julia" uniqKey="Ladewig J" first="Julia" last="Ladewig">Julia Ladewig</name><affiliation><nlm:aff id="aff1">Institute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Kesavan, Jaideep C" sort="Kesavan, Jaideep C" uniqKey="Kesavan J" first="Jaideep C." last="Kesavan">Jaideep C. Kesavan</name><affiliation><nlm:aff id="aff1">Institute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Vandenberghe, Rik" sort="Vandenberghe, Rik" uniqKey="Vandenberghe R" first="Rik" last="Vandenberghe">Rik Vandenberghe</name><affiliation><nlm:aff id="aff4">Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium</nlm:aff></affiliation><affiliation><nlm:aff id="aff5">Laboratory for Cognitive Neurology, Department of Neurosciences, University of Leuven, 3000 Leuven, Belgium</nlm:aff></affiliation></author><author><name sortKey="Vandenbulcke, Mathieu" sort="Vandenbulcke, Mathieu" uniqKey="Vandenbulcke M" first="Mathieu" last="Vandenbulcke">Mathieu Vandenbulcke</name><affiliation><nlm:aff id="aff6">Department of Old Age Psychiatry, University Hospitals Leuven, 3000 Leuven, Belgium</nlm:aff></affiliation></author><author><name sortKey="Van Damme, Philip" sort="Van Damme, Philip" uniqKey="Van Damme P" first="Philip" last="Van Damme">Philip Van Damme</name><affiliation><nlm:aff id="aff4">Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium</nlm:aff></affiliation><affiliation><nlm:aff id="aff5">Laboratory for Cognitive Neurology, Department of Neurosciences, University of Leuven, 3000 Leuven, Belgium</nlm:aff></affiliation><affiliation><nlm:aff id="aff7">Vesalius Research Center, VIB, 3000 Leuven, Belgium</nlm:aff></affiliation></author><author><name sortKey="Walter, Jochen" sort="Walter, Jochen" uniqKey="Walter J" first="Jochen" last="Walter">Jochen Walter</name><affiliation><nlm:aff id="aff3">Department of Neurology, University of Bonn, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Brustle, Oliver" sort="Brustle, Oliver" uniqKey="Brustle O" first="Oliver" last="Brüstle">Oliver Brüstle</name><affiliation><nlm:aff id="aff1">Institute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, 53127 Bonn, Germany</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">Life&Brain GmbH, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Koch, Philipp" sort="Koch, Philipp" uniqKey="Koch P" first="Philipp" last="Koch">Philipp Koch</name><affiliation><nlm:aff id="aff1">Institute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, 53127 Bonn, Germany</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">Life&Brain GmbH, 53127 Bonn, Germany</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24371804</idno><idno type="pmc">3871388</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871388</idno><idno type="RBID">PMC:3871388</idno><idno type="doi">10.1016/j.stemcr.2013.10.011</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">000260</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">APP Processing in Human Pluripotent Stem Cell-Derived Neurons Is Resistant to NSAID-Based γ-Secretase Modulation</title><author><name sortKey="Mertens, Jerome" sort="Mertens, Jerome" uniqKey="Mertens J" first="Jerome" last="Mertens">Jerome Mertens</name><affiliation><nlm:aff id="aff1">Institute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Stuber, Kathrin" sort="Stuber, Kathrin" uniqKey="Stuber K" first="Kathrin" last="Stüber">Kathrin Stüber</name><affiliation><nlm:aff id="aff1">Institute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, 53127 Bonn, Germany</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">Life&Brain GmbH, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Wunderlich, Patrick" sort="Wunderlich, Patrick" uniqKey="Wunderlich P" first="Patrick" last="Wunderlich">Patrick Wunderlich</name><affiliation><nlm:aff id="aff3">Department of Neurology, University of Bonn, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Ladewig, Julia" sort="Ladewig, Julia" uniqKey="Ladewig J" first="Julia" last="Ladewig">Julia Ladewig</name><affiliation><nlm:aff id="aff1">Institute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Kesavan, Jaideep C" sort="Kesavan, Jaideep C" uniqKey="Kesavan J" first="Jaideep C." last="Kesavan">Jaideep C. Kesavan</name><affiliation><nlm:aff id="aff1">Institute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Vandenberghe, Rik" sort="Vandenberghe, Rik" uniqKey="Vandenberghe R" first="Rik" last="Vandenberghe">Rik Vandenberghe</name><affiliation><nlm:aff id="aff4">Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium</nlm:aff></affiliation><affiliation><nlm:aff id="aff5">Laboratory for Cognitive Neurology, Department of Neurosciences, University of Leuven, 3000 Leuven, Belgium</nlm:aff></affiliation></author><author><name sortKey="Vandenbulcke, Mathieu" sort="Vandenbulcke, Mathieu" uniqKey="Vandenbulcke M" first="Mathieu" last="Vandenbulcke">Mathieu Vandenbulcke</name><affiliation><nlm:aff id="aff6">Department of Old Age Psychiatry, University Hospitals Leuven, 3000 Leuven, Belgium</nlm:aff></affiliation></author><author><name sortKey="Van Damme, Philip" sort="Van Damme, Philip" uniqKey="Van Damme P" first="Philip" last="Van Damme">Philip Van Damme</name><affiliation><nlm:aff id="aff4">Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium</nlm:aff></affiliation><affiliation><nlm:aff id="aff5">Laboratory for Cognitive Neurology, Department of Neurosciences, University of Leuven, 3000 Leuven, Belgium</nlm:aff></affiliation><affiliation><nlm:aff id="aff7">Vesalius Research Center, VIB, 3000 Leuven, Belgium</nlm:aff></affiliation></author><author><name sortKey="Walter, Jochen" sort="Walter, Jochen" uniqKey="Walter J" first="Jochen" last="Walter">Jochen Walter</name><affiliation><nlm:aff id="aff3">Department of Neurology, University of Bonn, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Brustle, Oliver" sort="Brustle, Oliver" uniqKey="Brustle O" first="Oliver" last="Brüstle">Oliver Brüstle</name><affiliation><nlm:aff id="aff1">Institute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, 53127 Bonn, Germany</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">Life&Brain GmbH, 53127 Bonn, Germany</nlm:aff></affiliation></author><author><name sortKey="Koch, Philipp" sort="Koch, Philipp" uniqKey="Koch P" first="Philipp" last="Koch">Philipp Koch</name><affiliation><nlm:aff id="aff1">Institute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, 53127 Bonn, Germany</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">Life&Brain GmbH, 53127 Bonn, Germany</nlm:aff></affiliation></author></analytic><series><title level="j">Stem Cell Reports</title><idno type="eISSN">2213-6711</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Summary</title><p>Increasing evidence suggests that elevated Aβ42 fractions in the brain cause Alzheimer’s disease (AD). Although γ-secretase modulators (GSMs), including a set of nonsteroidal anti-inflammatory drugs (NSAIDs), were found to lower Aβ42 in various model systems, NSAID-based GSMs proved to be surprisingly inefficient in human clinical trials. Reasoning that the nonhuman and nonneuronal cells typically used in pharmaceutical compound validation might not adequately reflect the drug responses of human neurons, we used human pluripotent stem cell-derived neurons from AD patients and unaffected donors to explore the efficacy of NSAID-based γ-secretase modulation. We found that pharmaceutically relevant concentrations of these GSMs that are clearly efficacious in conventional nonneuronal cell models fail to elicit any effect on Aβ42/Aß40 ratios in human neurons. Our work reveals resistance of human neurons to NSAID-based γ-secretase modulation, highlighting the need to validate compound efficacy directly in the human cell type affected by the respective disease.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Bannwarth, B" uniqKey="Bannwarth B">B. Bannwarth</name></author><author><name sortKey="Netter, P" uniqKey="Netter P">P. Netter</name></author><author><name sortKey="Lapicque, F" uniqKey="Lapicque F">F. Lapicque</name></author><author><name sortKey="Pere, P" uniqKey="Pere P">P. Péré</name></author><author><name sortKey="Thomas, P" uniqKey="Thomas P">P. Thomas</name></author><author><name sortKey="Gaucher, A" uniqKey="Gaucher A">A. Gaucher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Blennow, K" uniqKey="Blennow K">K. Blennow</name></author><author><name sortKey="Zetterberg, H" uniqKey="Zetterberg H">H. Zetterberg</name></author><author><name sortKey="Fagan, A M" uniqKey="Fagan A">A.M. Fagan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Borchelt, D R" uniqKey="Borchelt D">D.R. Borchelt</name></author><author><name sortKey="Thinakaran, G" uniqKey="Thinakaran G">G. Thinakaran</name></author><author><name sortKey="Eckman, C B" uniqKey="Eckman C">C.B. Eckman</name></author><author><name sortKey="Lee, M K" uniqKey="Lee M">M.K. Lee</name></author><author><name sortKey="Davenport, F" uniqKey="Davenport F">F. Davenport</name></author><author><name sortKey="Ratovitsky, T" uniqKey="Ratovitsky T">T. Ratovitsky</name></author><author><name sortKey="Prada, C M" uniqKey="Prada C">C.M. Prada</name></author><author><name sortKey="Kim, G" uniqKey="Kim G">G. Kim</name></author><author><name sortKey="Seekins, S" uniqKey="Seekins S">S. Seekins</name></author><author><name sortKey="Yager, D" uniqKey="Yager D">D. Yager</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Citron, M" uniqKey="Citron M">M. Citron</name></author><author><name sortKey="Oltersdorf, T" uniqKey="Oltersdorf T">T. Oltersdorf</name></author><author><name sortKey="Haass, C" uniqKey="Haass C">C. Haass</name></author><author><name sortKey="Mcconlogue, L" uniqKey="Mcconlogue L">L. McConlogue</name></author><author><name sortKey="Hung, A Y" uniqKey="Hung A">A.Y. Hung</name></author><author><name sortKey="Seubert, P" uniqKey="Seubert P">P. Seubert</name></author><author><name sortKey="Vigo Pelfrey, C" uniqKey="Vigo Pelfrey C">C. Vigo-Pelfrey</name></author><author><name sortKey="Lieberburg, I" uniqKey="Lieberburg I">I. Lieberburg</name></author><author><name sortKey="Selkoe, D J" uniqKey="Selkoe D">D.J. Selkoe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Jong, D" uniqKey="De Jong D">D. de Jong</name></author><author><name sortKey="Jansen, R" uniqKey="Jansen R">R. Jansen</name></author><author><name sortKey="Hoefnagels, W" uniqKey="Hoefnagels W">W. Hoefnagels</name></author><author><name sortKey="Jellesma Eggenkamp, M" uniqKey="Jellesma Eggenkamp M">M. Jellesma-Eggenkamp</name></author><author><name sortKey="Verbeek, M" uniqKey="Verbeek M">M. Verbeek</name></author><author><name sortKey="Borm, G" uniqKey="Borm G">G. Borm</name></author><author><name sortKey="Kremer, B" uniqKey="Kremer B">B. Kremer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Eriksen, J L" uniqKey="Eriksen J">J.L. Eriksen</name></author><author><name sortKey="Sagi, S A" uniqKey="Sagi S">S.A. Sagi</name></author><author><name sortKey="Smith, T E" uniqKey="Smith T">T.E. Smith</name></author><author><name sortKey="Weggen, S" uniqKey="Weggen S">S. Weggen</name></author><author><name sortKey="Das, P" uniqKey="Das P">P. Das</name></author><author><name sortKey="Mclendon, D C" uniqKey="Mclendon D">D.C. McLendon</name></author><author><name sortKey="Ozols, V V" uniqKey="Ozols V">V.V. Ozols</name></author><author><name sortKey="Jessing, K W" uniqKey="Jessing K">K.W. Jessing</name></author><author><name sortKey="Zavitz, K H" uniqKey="Zavitz K">K.H. Zavitz</name></author><author><name sortKey="Koo, E H" uniqKey="Koo E">E.H. Koo</name></author><author><name sortKey="Golde, T E" uniqKey="Golde T">T.E. Golde</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Falk, A" uniqKey="Falk A">A. Falk</name></author><author><name sortKey="Koch, P" uniqKey="Koch P">P. Koch</name></author><author><name sortKey="Kesavan, J" uniqKey="Kesavan J">J. Kesavan</name></author><author><name sortKey="Takashima, Y" uniqKey="Takashima Y">Y. Takashima</name></author><author><name sortKey="Ladewig, J" uniqKey="Ladewig J">J. Ladewig</name></author><author><name sortKey="Alexander, M" uniqKey="Alexander M">M. Alexander</name></author><author><name sortKey="Wiskow, O" uniqKey="Wiskow O">O. Wiskow</name></author><author><name sortKey="Tailor, J" uniqKey="Tailor J">J. Tailor</name></author><author><name sortKey="Trotter, M" uniqKey="Trotter M">M. Trotter</name></author><author><name sortKey="Pollard, S" uniqKey="Pollard S">S. Pollard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galasko, D R" uniqKey="Galasko D">D.R. Galasko</name></author><author><name sortKey="Graff Radford, N" uniqKey="Graff Radford N">N. Graff-Radford</name></author><author><name sortKey="May, S" uniqKey="May S">S. May</name></author><author><name sortKey="Hendrix, S" uniqKey="Hendrix S">S. Hendrix</name></author><author><name sortKey="Cottrell, B A" uniqKey="Cottrell B">B.A. Cottrell</name></author><author><name sortKey="Sagi, S A" uniqKey="Sagi S">S.A. Sagi</name></author><author><name sortKey="Mather, G" uniqKey="Mather G">G. Mather</name></author><author><name sortKey="Laughlin, M" uniqKey="Laughlin M">M. Laughlin</name></author><author><name sortKey="Zavitz, K H" uniqKey="Zavitz K">K.H. Zavitz</name></author><author><name sortKey="Swabb, E" uniqKey="Swabb E">E. Swabb</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ghosh, A K" uniqKey="Ghosh A">A.K. Ghosh</name></author><author><name sortKey="Brindisi, M" uniqKey="Brindisi M">M. Brindisi</name></author><author><name sortKey="Tang, J" uniqKey="Tang J">J. Tang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Golde, T E" uniqKey="Golde T">T.E. Golde</name></author><author><name sortKey="Schneider, L S" uniqKey="Schneider L">L.S. Schneider</name></author><author><name sortKey="Koo, E H" uniqKey="Koo E">E.H. Koo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Green, R C" uniqKey="Green R">R.C. Green</name></author><author><name sortKey="Schneider, L S" uniqKey="Schneider L">L.S. Schneider</name></author><author><name sortKey="Amato, D A" uniqKey="Amato D">D.A. Amato</name></author><author><name sortKey="Beelen, A P" uniqKey="Beelen A">A.P. Beelen</name></author><author><name sortKey="Wilcock, G" uniqKey="Wilcock G">G. Wilcock</name></author><author><name sortKey="Swabb, E A" uniqKey="Swabb E">E.A. Swabb</name></author><author><name sortKey="Zavitz, K H" uniqKey="Zavitz K">K.H. Zavitz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Haass, C" uniqKey="Haass C">C. Haass</name></author><author><name sortKey="Kaether, C" uniqKey="Kaether C">C. Kaether</name></author><author><name sortKey="Thinakaran, G" uniqKey="Thinakaran G">G. Thinakaran</name></author><author><name sortKey="Sisodia, S" uniqKey="Sisodia S">S. Sisodia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Imbimbo, B P" uniqKey="Imbimbo B">B.P. Imbimbo</name></author><author><name sortKey="Giardina, G A" uniqKey="Giardina G">G.A. Giardina</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Israel, M A" uniqKey="Israel M">M.A. Israel</name></author><author><name sortKey="Yuan, S H" uniqKey="Yuan S">S.H. Yuan</name></author><author><name sortKey="Bardy, C" uniqKey="Bardy C">C. Bardy</name></author><author><name sortKey="Reyna, S M" uniqKey="Reyna S">S.M. Reyna</name></author><author><name sortKey="Mu, Y" uniqKey="Mu Y">Y. Mu</name></author><author><name sortKey="Herrera, C" uniqKey="Herrera C">C. Herrera</name></author><author><name sortKey="Hefferan, M P" uniqKey="Hefferan M">M.P. Hefferan</name></author><author><name sortKey="Van Gorp, S" uniqKey="Van Gorp S">S. Van Gorp</name></author><author><name sortKey="Nazor, K L" uniqKey="Nazor K">K.L. Nazor</name></author><author><name sortKey="Boscolo, F S" uniqKey="Boscolo F">F.S. Boscolo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jumpertz, T" uniqKey="Jumpertz T">T. Jumpertz</name></author><author><name sortKey="Rennhack, A" uniqKey="Rennhack A">A. Rennhack</name></author><author><name sortKey="Ness, J" uniqKey="Ness J">J. Ness</name></author><author><name sortKey="Baches, S" uniqKey="Baches S">S. Baches</name></author><author><name sortKey="Pietrzik, C U" uniqKey="Pietrzik C">C.U. Pietrzik</name></author><author><name sortKey="Bulic, B" uniqKey="Bulic B">B. Bulic</name></author><author><name sortKey="Weggen, S" uniqKey="Weggen S">S. Weggen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Karran, E" uniqKey="Karran E">E. Karran</name></author><author><name sortKey="Mercken, M" uniqKey="Mercken M">M. Mercken</name></author><author><name sortKey="De Strooper, B" uniqKey="De Strooper B">B. De Strooper</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koch, P" uniqKey="Koch P">P. Koch</name></author><author><name sortKey="Opitz, T" uniqKey="Opitz T">T. Opitz</name></author><author><name sortKey="Steinbeck, J A" uniqKey="Steinbeck J">J.A. Steinbeck</name></author><author><name sortKey="Ladewig, J" uniqKey="Ladewig J">J. Ladewig</name></author><author><name sortKey="Brustle, O" uniqKey="Brustle O">O. Brüstle</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koch, P" uniqKey="Koch P">P. Koch</name></author><author><name sortKey="Breuer, P" uniqKey="Breuer P">P. Breuer</name></author><author><name sortKey="Peitz, M" uniqKey="Peitz M">M. Peitz</name></author><author><name sortKey="Jungverdorben, J" uniqKey="Jungverdorben J">J. Jungverdorben</name></author><author><name sortKey="Kesavan, J" uniqKey="Kesavan J">J. Kesavan</name></author><author><name sortKey="Poppe, D" uniqKey="Poppe D">D. Poppe</name></author><author><name sortKey="Doerr, J" uniqKey="Doerr J">J. Doerr</name></author><author><name sortKey="Ladewig, J" uniqKey="Ladewig J">J. Ladewig</name></author><author><name sortKey="Mertens, J" uniqKey="Mertens J">J. Mertens</name></author><author><name sortKey="Tuting, T" uniqKey="Tuting T">T. Tüting</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koch, P" uniqKey="Koch P">P. Koch</name></author><author><name sortKey="Tamboli, I Y" uniqKey="Tamboli I">I.Y. Tamboli</name></author><author><name sortKey="Mertens, J" uniqKey="Mertens J">J. Mertens</name></author><author><name sortKey="Wunderlich, P" uniqKey="Wunderlich P">P. Wunderlich</name></author><author><name sortKey="Ladewig, J" uniqKey="Ladewig J">J. Ladewig</name></author><author><name sortKey="Stuber, K" uniqKey="Stuber K">K. Stüber</name></author><author><name sortKey="Esselmann, H" uniqKey="Esselmann H">H. Esselmann</name></author><author><name sortKey="Wiltfang, J" uniqKey="Wiltfang J">J. Wiltfang</name></author><author><name sortKey="Brustle, O" uniqKey="Brustle O">O. Brüstle</name></author><author><name sortKey="Walter, J" uniqKey="Walter J">J. Walter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kukar, T L" uniqKey="Kukar T">T.L. Kukar</name></author><author><name sortKey="Ladd, T B" uniqKey="Ladd T">T.B. Ladd</name></author><author><name sortKey="Bann, M A" uniqKey="Bann M">M.A. Bann</name></author><author><name sortKey="Fraering, P C" uniqKey="Fraering P">P.C. Fraering</name></author><author><name sortKey="Narlawar, R" uniqKey="Narlawar R">R. Narlawar</name></author><author><name sortKey="Maharvi, G M" uniqKey="Maharvi G">G.M. Maharvi</name></author><author><name sortKey="Healy, B" uniqKey="Healy B">B. Healy</name></author><author><name sortKey="Chapman, R" uniqKey="Chapman R">R. Chapman</name></author><author><name sortKey="Welzel, A T" uniqKey="Welzel A">A.T. Welzel</name></author><author><name sortKey="Price, R W" uniqKey="Price R">R.W. Price</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kumar Singh, S" uniqKey="Kumar Singh S">S. Kumar-Singh</name></author><author><name sortKey="Theuns, J" uniqKey="Theuns J">J. Theuns</name></author><author><name sortKey="Van Broeck, B" uniqKey="Van Broeck B">B. Van Broeck</name></author><author><name sortKey="Pirici, D" uniqKey="Pirici D">D. Pirici</name></author><author><name sortKey="Vennekens, K" uniqKey="Vennekens K">K. Vennekens</name></author><author><name sortKey="Corsmit, E" uniqKey="Corsmit E">E. Corsmit</name></author><author><name sortKey="Cruts, M" uniqKey="Cruts M">M. Cruts</name></author><author><name sortKey="Dermaut, B" uniqKey="Dermaut B">B. Dermaut</name></author><author><name sortKey="Wang, R" uniqKey="Wang R">R. Wang</name></author><author><name sortKey="Van Broeckhoven, C" uniqKey="Van Broeckhoven C">C. Van Broeckhoven</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kumpulainen, E" uniqKey="Kumpulainen E">E. Kumpulainen</name></author><author><name sortKey="V Litalo, P" uniqKey="V Litalo P">P. Välitalo</name></author><author><name sortKey="Kokki, M" uniqKey="Kokki M">M. Kokki</name></author><author><name sortKey="Lehtonen, M" uniqKey="Lehtonen M">M. Lehtonen</name></author><author><name sortKey="Hooker, A" uniqKey="Hooker A">A. Hooker</name></author><author><name sortKey="Ranta, V P" uniqKey="Ranta V">V.P. Ranta</name></author><author><name sortKey="Kokki, H" uniqKey="Kokki H">H. Kokki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Larner, A J" uniqKey="Larner A">A.J. Larner</name></author><author><name sortKey="Doran, M" uniqKey="Doran M">M. Doran</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mattis, V B" uniqKey="Mattis V">V.B. Mattis</name></author><author><name sortKey="Svendsen, C N" uniqKey="Svendsen C">C.N. Svendsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mertens, J" uniqKey="Mertens J">J. Mertens</name></author><author><name sortKey="Stuber, K" uniqKey="Stuber K">K. Stüber</name></author><author><name sortKey="Poppe, D" uniqKey="Poppe D">D. Poppe</name></author><author><name sortKey="Doerr, J" uniqKey="Doerr J">J. Doerr</name></author><author><name sortKey="Ladewig, J" uniqKey="Ladewig J">J. Ladewig</name></author><author><name sortKey="Brustle, O" uniqKey="Brustle O">O. Brüstle</name></author><author><name sortKey="Koch, P" uniqKey="Koch P">P. Koch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rajendran, L" uniqKey="Rajendran L">L. Rajendran</name></author><author><name sortKey="Knolker, H J" uniqKey="Knolker H">H.J. Knölker</name></author><author><name sortKey="Simons, K" uniqKey="Simons K">K. Simons</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ritschel, W A" uniqKey="Ritschel W">W.A. Ritschel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Selkoe, D J" uniqKey="Selkoe D">D.J. Selkoe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Selkoe, D" uniqKey="Selkoe D">D. Selkoe</name></author><author><name sortKey="Mandelkow, E" uniqKey="Mandelkow E">E. Mandelkow</name></author><author><name sortKey="Holtzman, D" uniqKey="Holtzman D">D. Holtzman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Takahashi, K" uniqKey="Takahashi K">K. Takahashi</name></author><author><name sortKey="Tanabe, K" uniqKey="Tanabe K">K. Tanabe</name></author><author><name sortKey="Ohnuki, M" uniqKey="Ohnuki M">M. Ohnuki</name></author><author><name sortKey="Narita, M" uniqKey="Narita M">M. Narita</name></author><author><name sortKey="Ichisaka, T" uniqKey="Ichisaka T">T. Ichisaka</name></author><author><name sortKey="Tomoda, K" uniqKey="Tomoda K">K. Tomoda</name></author><author><name sortKey="Yamanaka, S" uniqKey="Yamanaka S">S. Yamanaka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Theuns, J" uniqKey="Theuns J">J. Theuns</name></author><author><name sortKey="Marjaux, E" uniqKey="Marjaux E">E. Marjaux</name></author><author><name sortKey="Vandenbulcke, M" uniqKey="Vandenbulcke M">M. Vandenbulcke</name></author><author><name sortKey="Van Laere, K" uniqKey="Van Laere K">K. Van Laere</name></author><author><name sortKey="Kumar Singh, S" uniqKey="Kumar Singh S">S. Kumar-Singh</name></author><author><name sortKey="Bormans, G" uniqKey="Bormans G">G. Bormans</name></author><author><name sortKey="Brouwers, N" uniqKey="Brouwers N">N. Brouwers</name></author><author><name sortKey="Van Den Broeck, M" uniqKey="Van Den Broeck M">M. Van den Broeck</name></author><author><name sortKey="Vennekens, K" uniqKey="Vennekens K">K. Vennekens</name></author><author><name sortKey="Corsmit, E" uniqKey="Corsmit E">E. Corsmit</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vellas, B" uniqKey="Vellas B">B. Vellas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weggen, S" uniqKey="Weggen S">S. Weggen</name></author><author><name sortKey="Eriksen, J L" uniqKey="Eriksen J">J.L. Eriksen</name></author><author><name sortKey="Das, P" uniqKey="Das P">P. Das</name></author><author><name sortKey="Sagi, S A" uniqKey="Sagi S">S.A. Sagi</name></author><author><name sortKey="Wang, R" uniqKey="Wang R">R. Wang</name></author><author><name sortKey="Pietrzik, C U" uniqKey="Pietrzik C">C.U. Pietrzik</name></author><author><name sortKey="Findlay, K A" uniqKey="Findlay K">K.A. Findlay</name></author><author><name sortKey="Smith, T E" uniqKey="Smith T">T.E. Smith</name></author><author><name sortKey="Murphy, M P" uniqKey="Murphy M">M.P. Murphy</name></author><author><name sortKey="Bulter, T" uniqKey="Bulter T">T. Bulter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wiltfang, J" uniqKey="Wiltfang J">J. Wiltfang</name></author><author><name sortKey="Esselmann, H" uniqKey="Esselmann H">H. Esselmann</name></author><author><name sortKey="Cupers, P" uniqKey="Cupers P">P. Cupers</name></author><author><name sortKey="Neumann, M" uniqKey="Neumann M">M. Neumann</name></author><author><name sortKey="Kretzschmar, H" uniqKey="Kretzschmar H">H. Kretzschmar</name></author><author><name sortKey="Beyermann, M" uniqKey="Beyermann M">M. Beyermann</name></author><author><name sortKey="Schleuder, D" uniqKey="Schleuder D">D. Schleuder</name></author><author><name sortKey="Jahn, H" uniqKey="Jahn H">H. Jahn</name></author><author><name sortKey="Ruther, E" uniqKey="Ruther E">E. Rüther</name></author><author><name sortKey="Kornhuber, J" uniqKey="Kornhuber J">J. Kornhuber</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="brief-report"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Stem Cell Reports</journal-id><journal-id journal-id-type="iso-abbrev">Stem Cell Reports</journal-id><journal-title-group><journal-title>Stem Cell Reports</journal-title></journal-title-group><issn pub-type="epub">2213-6711</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24371804</article-id><article-id pub-id-type="pmc">3871388</article-id><article-id pub-id-type="publisher-id">S2213-6711(13)00123-9</article-id><article-id pub-id-type="doi">10.1016/j.stemcr.2013.10.011</article-id><article-categories><subj-group subj-group-type="heading"><subject>Report</subject></subj-group></article-categories><title-group><article-title>APP Processing in Human Pluripotent Stem Cell-Derived Neurons Is Resistant to NSAID-Based γ-Secretase Modulation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mertens</surname><given-names>Jerome</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">8</xref></contrib><contrib contrib-type="author"><name><surname>Stüber</surname><given-names>Kathrin</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Wunderlich</surname><given-names>Patrick</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Ladewig</surname><given-names>Julia</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kesavan</surname><given-names>Jaideep C.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Vandenberghe</surname><given-names>Rik</given-names></name><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Vandenbulcke</surname><given-names>Mathieu</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>van Damme</surname><given-names>Philip</given-names></name><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Walter</surname><given-names>Jochen</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Brüstle</surname><given-names>Oliver</given-names></name><email>brustle@uni-bonn.de</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">∗</xref></contrib><contrib contrib-type="author"><name><surname>Koch</surname><given-names>Philipp</given-names></name><email>philipp.koch@uni-bonn.de</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor2" ref-type="corresp">∗∗</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Institute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, 53127 Bonn, Germany</aff><aff id="aff2"><label>2</label>Life&Brain GmbH, 53127 Bonn, Germany</aff><aff id="aff3"><label>3</label>Department of Neurology, University of Bonn, 53127 Bonn, Germany</aff><aff id="aff4"><label>4</label>Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium</aff><aff id="aff5"><label>5</label>Laboratory for Cognitive Neurology, Department of Neurosciences, University of Leuven, 3000 Leuven, Belgium</aff><aff id="aff6"><label>6</label>Department of Old Age Psychiatry, University Hospitals Leuven, 3000 Leuven, Belgium</aff><aff id="aff7"><label>7</label>Vesalius Research Center, VIB, 3000 Leuven, Belgium</aff><author-notes><corresp id="cor1"><label>∗</label>Corresponding author <email>brustle@uni-bonn.de</email></corresp><corresp id="cor2"><label>∗∗</label>Corresponding author <email>philipp.koch@uni-bonn.de</email></corresp><fn id="fn1"><label>8</label><p>Present address: Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA</p></fn></author-notes><pub-date pub-type="pmc-release"><day>5</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>5</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="collection"><day>17</day><month>12</month><year>2013</year></pub-date><volume>1</volume><issue>6</issue><fpage>491</fpage><lpage>498</lpage><history><date date-type="received"><day>31</day><month>5</month><year>2013</year></date><date date-type="rev-recd"><day>25</day><month>10</month><year>2013</year></date><date date-type="accepted"><day>26</day><month>10</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 The Authors</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><title>Summary</title><p>Increasing evidence suggests that elevated Aβ42 fractions in the brain cause Alzheimer’s disease (AD). Although γ-secretase modulators (GSMs), including a set of nonsteroidal anti-inflammatory drugs (NSAIDs), were found to lower Aβ42 in various model systems, NSAID-based GSMs proved to be surprisingly inefficient in human clinical trials. Reasoning that the nonhuman and nonneuronal cells typically used in pharmaceutical compound validation might not adequately reflect the drug responses of human neurons, we used human pluripotent stem cell-derived neurons from AD patients and unaffected donors to explore the efficacy of NSAID-based γ-secretase modulation. We found that pharmaceutically relevant concentrations of these GSMs that are clearly efficacious in conventional nonneuronal cell models fail to elicit any effect on Aβ42/Aß40 ratios in human neurons. Our work reveals resistance of human neurons to NSAID-based γ-secretase modulation, highlighting the need to validate compound efficacy directly in the human cell type affected by the respective disease.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1"></graphic></fig></abstract><abstract abstract-type="author-highlights"><title>Highlights</title><p><list list-type="simple"><list-item id="u0010"><label>•</label><p>iPSC-derived neurons from Alzheimer patients exhibit elevated Aβ42/Aß40 ratios</p></list-item><list-item id="u0015"><label>•</label><p>Human neurons are resistant to NSAID-based γ-secretase modulation</p></list-item></list></p></abstract><abstract abstract-type="teaser"><p>Koch, Brüstle, and colleagues employed induced pluripotent stem cell-derived neurons (iPSC-Ns) to explore the clinical failure of NSAID-based γ-secretase modulators in the treatment of Alzheimer’s disease (AD). In contrast to the nonneuronal cells typically used in pharmaceutical screening, iPSC-Ns from healthy donors and AD patients were found to exhibit a remarkable resistance to this compound family, thereby supporting the value of iPSCs for predicting drug responsiveness.</p></abstract></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Alzheimer’s disease (AD) is a common and fatal neurodegenerative disorder. Currently, no effective drugs that can stop, slow, or prevent disease progression are available. Deposition of amyloid plaques consisting of aggregated Aβ peptides in the brain is a hallmark of the disease (<xref rid="bib28" ref-type="bibr">Selkoe, 2001</xref>). The amyloid cascade hypothesis presumes that the accumulation and oligomerization of Aβ peptides trigger a complex pathological cascade resulting in synaptic dysfunction, tau hyperphosphorylation, and eventually progressive neurodegeneration and dementia (<xref rid="bib29" ref-type="bibr">Selkoe et al., 2012</xref>). Aβ is a proteolytic derivative of the transmembrane amyloid precursor protein (APP), which is sequentially cleaved by β- and γ-secretases in the amyloidogenic processing pathway (<xref rid="bib12" ref-type="bibr">Haass et al., 2012</xref>). Intramembranous γ-secretase cleavage of the C-terminal fragments of APP (APP-CTF), which represent the immediate precursors of Aβ, results in multiple length variants of Aβ (<xref rid="bib12" ref-type="bibr">Haass et al., 2012</xref>). Longer Aβ variants such as Aβ42 and Aβ43 are more prone to aggregation and thus are considered more pathogenic than shorter ones such as Aβ38 and Aβ40 (<xref rid="bib16" ref-type="bibr">Karran et al., 2011</xref>). Today, the peptide ratio of Aβ42 to Aβ40 in the cerebrospinal fluid (CSF) represents the most sensitive and specific primary biomarker for AD and inversely correlates with the age of disease onset in both sporadic (<xref rid="bib2" ref-type="bibr">Blennow et al., 2012</xref>) and familial (<xref rid="bib21" ref-type="bibr">Kumar-Singh et al., 2006</xref>) forms of AD. Mutations in APP or in the γ-secretase subunits presenilin-1 (PS1) and PS2 are the main cause of autosomal-inherited early-onset forms of AD and commonly lead to increased Aβ42/Aß40 ratios and/or overall elevated levels of Aβ. These observations suggest that misprocessing of APP with a consecutive increase of Aβ42/Aß40 ratios is characteristic of and, most probably, causative for sporadic and familial AD (<xref rid="bib34" ref-type="bibr">Wiltfang et al., 2001</xref>). Based on this hypothesis, several antiamyloidogenic drugs, including compounds that inhibit β- and γ-secretase activity, have been developed (<xref rid="bib9 bib13" ref-type="bibr">Ghosh et al., 2012; Imbimbo and Giardina, 2011</xref>). Interestingly, a subset of nonsteroidal anti-inflammatory drugs (NSAIDs) were identified to act as γ-secretase modulators (GSMs) that specifically lower the production of Aβ42 in favor of shorter Aβ isoforms by targeting γ-secretase PS1 or its substrate APP (<xref rid="bib15 bib20 bib33" ref-type="bibr">Jumpertz et al., 2012; Kukar et al., 2008; Weggen et al., 2001</xref>). Unfortunately, and despite solid preclinical data acquired using transgenic animals and APP-transgenic cell lines, NSAIDs such as flurbiprofen and indometacin were not effective in delaying disease progression in mild-to-moderate AD patients in phase 2 and phase 3 clinical trials (<xref rid="bib5 bib6 bib11 bib13 bib32" ref-type="bibr">de Jong et al., 2008; Eriksen et al., 2003; Green et al., 2009; Imbimbo and Giardina, 2011; Vellas, 2010</xref>). The reasons for these negative outcomes are speculative and have been in part attributed to inappropriate study design, as symptomatic AD patients were treated when the disease may have already been irreversibly advanced (<xref rid="bib10" ref-type="bibr">Golde et al., 2011</xref>). Also, it remains unclear whether the trialed GSMs indeed lowered Aβ42 levels in the human brain, leaving the important question as to whether γ-secretase modulation is a valid approach in AD therapy unresolved. Further, insufficient brain penetration of the tested compounds, as well as a general failure of the amyloid cascade hypothesis, has been considered (<xref rid="bib10" ref-type="bibr">Golde et al., 2011</xref>). Remarkably, the efficacy of GSMs in human neurons as the primary target cell type has never been directly explored. Recent advances in neural differentiation of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) enable the derivation of authentic neuronal cultures to dissect the pathological mechanisms relevant to AD and drug testing (<xref rid="bib14 bib19 bib24 bib25" ref-type="bibr">Israel et al., 2012; Koch et al., 2012; Mattis and Svendsen, 2011; Mertens et al., 2013</xref>). Here, we used this approach to determine the efficacy of NSAIDs previously employed in clinical GSM trials in human neurons derived from iPSCs of patients with familial AD and unaffected controls (Ctrl; <xref rid="fig1" ref-type="fig">Figure 1</xref>A).</p></sec><sec id="sec2"><title>Results and Discussion</title><sec id="sec2.1"><title>Neurons Derived from Familial AD Patients Show Elevated Aβ42/Aβ40 Ratios</title><p>To elucidate APP processing in human neurons from various genetic backgrounds, we took advantage of our recently described and highly standardized pluripotent stem cell-derived, long-term self-renewing neural stem cells (lt-NES cells), which consistently give rise to cultures containing >70% functional human neurons (<xref rid="bib7 bib17" ref-type="bibr">Falk et al., 2012; Koch et al., 2009</xref>). We generated iPSCs from two patients with familial AD (two clones each). Patient AD-1 (AD-1a and AD-1b) carries an A79V substitution in one allele of the PS1 gene, which results in autosomal-dominant AD (<xref rid="bib23" ref-type="bibr">Larner and Doran, 2006</xref>). Patient AD-2 (AD-2a and AD-2b) carries a K724N mutation in the intracytosolic fragment of APP (for clinical details, see <xref rid="app2" ref-type="sec">Table S1</xref> available online; <xref rid="bib31" ref-type="bibr">Theuns et al., 2006</xref>). Characterization of the established iPSC lines revealed sustained silencing of the reprogramming transgenes, a normal karyotype, expression of pluripotency markers, and formation of teratomas upon in vivo transplantation (<xref rid="app2" ref-type="sec">Figures S1</xref>A–S1D). The four AD-patient-derived lines were subsequently differentiated into lt-NES cells according to established protocols (<xref rid="bib7 bib17" ref-type="bibr">Falk et al., 2012; Koch et al., 2009</xref>). We further included lt-NES cells derived from reprogrammed fibroblasts from three unaffected individuals (Ctrl-1: clone a and b; Ctrl-2: clone a and b; Ctrl-3: clone a) (<xref rid="bib7 bib18" ref-type="bibr">Falk et al., 2012; Koch et al., 2011</xref>) and from the hESC lines I3 and I6 (hES-1 and hES-2) (<xref rid="bib17" ref-type="bibr">Koch et al., 2009</xref>). All Ctrl and AD lt-NES cell lines expressed the rosette-associated neuroectodermal markers PLZF, Nestin, DACH1, SOX2, and apically accentuated ZO-1 (<xref rid="fig1" ref-type="fig">Figure 1</xref>B). Familial AD mutations were confirmed by sequencing genomic DNA from patient-derived lt-NES cells (<xref rid="app2" ref-type="sec">Figure S1</xref>E). Following differentiation for 4 weeks, 75%–85% of the cultures consisted of postmitotic neurons that expressed β-III tubulin and MAP2ab, while <10% of differentiated cells were positive for the glial marker glial fibrillary acidic protein (GFAP; <xref rid="fig1" ref-type="fig">Figure 1</xref>B). We further detected a consistent neuronal expression of PS1, APP, and phosphorylated Tau protein (PHF1 antibody; <xref rid="fig1" ref-type="fig">Figure 1</xref>B). Similarly to Ctrl neurons, which have been described previously (<xref rid="bib7 bib17" ref-type="bibr">Falk et al., 2012; Koch et al., 2009</xref>), the AD lt-NES cell-derived neurons developed mature functional properties, including the generation of action potentials upon depolarization and the establishment of spontaneously active synaptic circuitries (<xref rid="fig1" ref-type="fig">Figure 1</xref>C). The neuron-specific <italic>APP</italic><sub><italic>695</italic></sub> variant and β- and γ-secretase-associated genes were expressed at comparable levels in the neuronal cultures (<xref rid="app2" ref-type="sec">Figure S1</xref>F). We detected no apparent variations in neuronal differentiation efficiency, neuronal morphology, basic electrophysiological function, or marker expression in Ctrl and AD lt-NES cell-derived neurons.</p><p>Mutations in PS1 and APP are known to result in elevated Aβ42/Aß40 ratios in the CSF of familial AD patients (<xref rid="bib3 bib21" ref-type="bibr">Borchelt et al., 1996; Kumar-Singh et al., 2006</xref>). Hence, we determined the levels of secreted Aβ40 and Aβ42 in conditioned media of the generated Ctrl and AD neurons by ELISA and calculated the Aβ42/Aß40 ratio. No significant difference in the Aβ42/Aß40 ratio between hESC-derived (0.092 ± 0.017) and Ctrl-iPSC-derived (0.096 ± 0.008) neurons was detected (<xref rid="fig2" ref-type="fig">Figure 2</xref>A). In contrast, AD-1 and AD-2 neurons showed 37% and 89% increases in Aβ42/Aß40 ratios to 0.126 ± 0.001 and 0.174 ± 0.018, respectively (<xref rid="fig2" ref-type="fig">Figure 2</xref>A). Interestingly, the increased Aβ42/Aß40 ratio in AD-1a neurons was solely attributable to decreased secretion of total Aβ40 by 26%, with Aβ42 levels remaining comparable to those generated by hESC- and Ctrl-iPSC-derived neurons (<xref rid="fig2" ref-type="fig">Figure 2</xref>B). AD-2a neurons also exhibited a decrease in total Aβ40 secretion by 31%, but in addition showed a 33% increase in Aβ42 secretion, resulting in an overall higher increase in the Aβ42/Aß40 ratio (<xref rid="fig2" ref-type="fig">Figure 2</xref>B). Thus, elevated Aβ42/Aß40 ratios in PS1(A79V) mutant neurons are likely due to a partial loss of function in γ-secretase function, while neurons from the patient with the APP(K724N) mutation showed decreased Aβ40 production in combination with a gain of function in Aβ42 secretion (<xref rid="bib19" ref-type="bibr">Koch et al., 2012</xref>). Interestingly, this might reflect the fact that although both mutations typically result in early-onset familial AD (age of onset: 52–59 years), PS1(A79V) is considered a “weak” mutation with a slowly progressing pathogenesis, whereas patients carrying the APP(K724N) mutation typically suffer from a rapid pathogenesis (<xref rid="bib23" ref-type="bibr">Larner and Doran, 2006</xref>).</p></sec><sec id="sec2.2"><title>NSAID-Based GSMs Can Lower Aβ42/Aβ40 Ratios at High Concentrations</title><p>To explore how known NSAID-based GSMs impact endogenous γ-secretase activity and thus influence the generation of Aβ42 and Aβ40 in human neurons, we first applied a set of ten candidate compounds to hESC-derived neurons (<xref rid="app2" ref-type="sec">Figures S2</xref>A and S2B). Secreted Aβ40 and Aβ42 levels were determined by ELISA after 36 hr of treatment. We found that indometacin, ibuprofen, diclofenac, and flurbiprofen significantly reduced the Aβ42/Aß40 ratio at 200 μM, with indometacin and flurbiprofen exhibiting the strongest effects (<xref rid="app2" ref-type="sec">Figure S2</xref>A). Direct γ-secretase inhibition by N-[N-(3,5-difluorophenacetyl)-1-alanyl]-S-phenylglycine t-butyl ester (DAPT; 10 μM) or inhibition of the γ-secretase activating protein (GSAP) by imatinib (10 μM) resulted in a strong decrease in both Aβ variants. Treatment with SC-560 (200 μM) specifically inhibited Aβ40 secretion, thereby leading to a 3-fold increased Aβ42/Aß40 ratio. Aspirin (250 μM) and naproxen (200 μM), as well as the ROCK (Rho-associated coiled coil forming protein serine/threonine kinase) inhibitor Y-27632 (5 μM), had no detectable effects on the neurons (<xref rid="app2" ref-type="sec">Figures S2</xref>A and S2B). We next tested the four identified NSAID-based GSMs on an extended set of Ctrl- and AD-patient-derived neurons. Ibuprofen and diclofenac (200 μM) reduced the Aβ42/Aß40 ratio by 25.0%–36.5% in all Ctrl- and AD-patient-derived neuronal cultures (<xref rid="fig2" ref-type="fig">Figure 2</xref>C). Flurbiprofen (200 μM) proved to be slightly more potent, as it consistently reduced the ratio by 37.5%–49.9% in all lines. Notably, the decrease in the Aβ42/Aβ40 ratio induced by 200 μM indometacin varied markedly between the cell lines, ranging between 10.0% ± 3.1% (AD-1a) and 75.0% ± 5.4% (Ctrl-1a). From these data, we conclude that neuronal cultures from AD-patient-derived iPSCs show pathologically altered Aβ generation, and that high concentrations of NSAID-based GSMs effectively lower Aβ42/Aß40 ratios in Ctrl- and AD-patient-derived neurons.</p></sec><sec id="sec2.3"><title>Human Neurons Do Not Respond to Therapeutically Relevant Concentrations of GSMs</title><p>Based on pharmacokinetic studies in humans, therapeutic dosages of most NSAIDs result in CSF concentrations in the low micromolar range (<xref rid="bib27" ref-type="bibr">Ritschel, 1999</xref>). For example, maximum CSF levels can be expected to not exceed 30 μM for indometacin (<xref rid="bib1 bib27" ref-type="bibr">Bannwarth et al., 1990; Ritschel, 1999</xref>) and 2 μM for flurbiprofen (<xref rid="bib8 bib22" ref-type="bibr">Galasko et al., 2007; Kumpulainen et al., 2010</xref>). Such low micromolar concentrations were sufficient to decrease Aβ42/Aß40 ratios in human APP-transgenic rodent cells (e.g., Chinese hamster ovary [CHO] cells), human nonneural cell lines (e.g., human embryonic kidney [HEK] cells), and the brains of transgenic mice. For example, 25 μM indometacin reduced the Aβ42/Aβ40 ratio by ∼50% in CHO-APP cells and 1.3 μM flurbiprofen reduced Aβ42 levels by ∼80% in Tg2576 mice (<xref rid="bib6 bib33" ref-type="bibr">Eriksen et al., 2003; Weggen et al., 2001</xref>). Based on these promising preclinical results, indometacin and flurbiprofen were tested for their efficiency to delay cognitive decline in human clinical trials. Yet, these GSMs failed to show any significant effect on the course of the disease compared with placebo controls (<xref rid="bib5 bib11" ref-type="bibr">de Jong et al., 2008; Green et al., 2009</xref>).</p><p>To evaluate the potency of these clinically failed NSAID-based GSMs in modulating endogenous human neuronal Aβ generation at concentrations that can realistically be achieved in the human brain, we treated differentiated neuronal cultures from Ctrl and AD patients with increasing concentrations of indometacin, and measured Aβ40 and Aβ42 levels by ELISA in conditioned medium after 36 hr (<xref rid="fig3" ref-type="fig">Figure 3</xref>A). As controls, CHO cells overexpressing human APP<sub>695</sub>, APP<sub>SWE</sub> (containing the K670N/M671L double mutation), or HEK-APP<sub>SWE</sub> (<xref rid="bib4" ref-type="bibr">Citron et al., 1992</xref>) cells were treated in parallel. As expected, as little as 25 μM indometacin sufficed to reduce the Aβ42/Aβ40 ratio in CHO-APP cells by >50%, and by 22% in HEK-APP<sub>SWE</sub> cells. Surprisingly, and in contrast to the APP-transgenic cell lines, concentrations of up to 75 μM indometacin had no significant effect on the ratio of Aß42 to Aß40 generated from endogenous APP in human neurons from all five genetic backgrounds, including both AD patients (<xref rid="fig3" ref-type="fig">Figure 3</xref>A; for separate graphs, see <xref rid="app2" ref-type="sec">Figure S3</xref>A). Whereas the total levels of Aβ42 from CHO-APP<sub>695</sub> and HEK-APP<sub>SWE</sub> cells selectively decreased in a concentration-dependent manner, total secretion of Aβ40 and Aβ42 remained unaffected in the human neuronal cultures (<xref rid="fig3" ref-type="fig">Figure 3</xref>B). Similarly, human neurons also proved largely resistant to clinically relevant concentrations of flurbiprofen, while CHO-APP<sub>695</sub> and HEK-APP<sub>SWE</sub> cells displayed a strong dose-dependent response (<xref rid="fig3" ref-type="fig">Figure 3</xref>C; also see <xref rid="app2" ref-type="sec">Figure S3</xref>B). To exclude interference of culture-medium ingredients, we tested hESC- and iPSC-derived neurons in parallel with HEK-APP<sub>695</sub> cells in the identical serum-containing medium. Under these conditions as well, human neurons exhibited a specific resistance to GSM treatment (<xref rid="app2" ref-type="sec">Figure S3</xref>C). In order to detect a possible GSM-inactivating activity of human neurons, we preincubated drug-containing medium (indometacin or flurbiprofen; both 75 μM) on human neurons or CHO<sub>WT</sub> cells before transferring it to CHO-APP<sub>SWE</sub>. We found that preincubation on neurons or CHO<sub>WT</sub> did not reduce the drugs’ ability to decrease the Aß42/Aß40 ratio in CHO-APP<sub>SWE</sub> cells (<xref rid="app2" ref-type="sec">Figure S3</xref>D).</p><p>We next asked whether artificially high protein levels of APP/APP-CTFs might provoke an abnormally amplified GSM effect that is not observed at endogenous expression levels. To test this, we generated transgenic lt-NES cells that conditionally overexpress APP<sub>695</sub> when treated with doxycycline (tetOn). Transgenic APP<sub>695</sub> overexpression was induced following 4 weeks of differentiation. Interestingly, overexpressing hES-1-APP<sub>695</sub> neurons significantly responded to 75 μM flurbiprofen, whereas nontransgenic hES-1 neurons remained inert (<xref rid="fig3" ref-type="fig">Figure 3</xref>D). However, the effect was mild compared with that detected in CHO-APP<sub>695</sub> cells and was not observed when the APP overexpressing neurons were treated with 25 μM or 75 μM indometacin (<xref rid="app2" ref-type="sec">Figure S3</xref>E). A plausible explanation might be that the APP protein levels achieved in transgenic human neurons are still significantly lower than those in CHO cells and thus are only partially sufficient to evoke the pronounced effect seen in tumor cell lines (<xref rid="app2" ref-type="sec">Figure S3</xref>F). Although increased GSM responses can be triggered by exaggerated APP levels in neurons, the actual cause of the low GSM responsiveness of human neurons might be complex. For example, it could involve specific subcellular localizations and posttranslational modifications of the γ-secretase/APP complex and/or interactors that may be specifically regulated in human neurons, such as γ-secretase activating protein (GSAP) and CD147 (<xref rid="bib26" ref-type="bibr">Rajendran et al., 2010</xref>). Species-specific effects may also contribute to this phenomenon, as human HEK cells consistently showed weaker responses to GSMs as compared with rodent CHO cells.</p><p>Taken together, our experiments reveal a cell-type-specific resistance of human neurons to pharmacologically relevant concentrations of known NSAID-based GSMs that stands in sharp contrast to widely used conventional model and drug-screening systems. Thus, it appears to be conceivable that data generated using APP-overexpressing cell lines and APP-transgenic mouse models have led to an overestimation of GSM efficacy in human neurons, a hypothesis that is supported by the clinical failure of this class of compounds. Extrapolating from our data, we conclude that much higher CSF concentrations of these NSAID-based GSMs would have been required to elicit beneficial effects in the human CNS. Our findings also strongly underline the importance and necessity of assessing compound efficacy in the appropriate human target cell type. Although in the past this route has been restricted due to the lack of primary tissue, the availability of hESCs and iPSCs now provides unprecedented opportunities for drug screening and preclinical compound validation in cell type-, disease-, and even patient-specific cell culture models.</p></sec></sec><sec sec-type="methods" id="sec3"><title>Experimental Procedures</title><sec id="sec3.1"><title>Culture and Differentiation of lt-NES Cells</title><p>Lt-NES cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)/F12, 2 mM L-glutamine, 1.6 g/l glucose, 0.1 mg/ml penicillin/streptomycin, N2 supplement (high transferrin; PAA), B27 (1 μl/ml; Life Technologies), and fibroblast growth factor 2 (FGF2) and epidermal growth factor (EGF; both 10 ng/ml; R&D Systems) on tissue culture plates coated with poly-L-ornithine/laminin (both Sigma), and passaged every 3–4 days. Neuronal differentiation was induced by withdrawal of FGF2 and EGF in differentiation media (Neurobasal medium supplemented with B27 [1:50; Life Technologies] and DMEM/F12 supplemented with N2 mixed at a 1:1 ratio and containing 300 ng/ml cyclic AMP) that was exchanged every second day (<xref rid="bib17" ref-type="bibr">Koch et al., 2009</xref>).</p><p>The study was approved by the local ethics committee.</p></sec><sec id="sec3.2"><title>Treatment of Cells with GSMs and Other Small Molecules</title><p>Cells were pretreated for 12 hr with medium containing the respective compound. Then the drug-containing medium was replaced and, 24 hr later, subjected to ELISA measurements. Stock solutions were as follows: ibuprofen (200 mM; Alexis Biochemicals), diclofenac (200 mM), naproxen (200 mM), flurbiprofen (200 mM), aspirin (250 mM), indometacin (50 mM; Cayman Chemical), SC-560 (200 mM), imatinib (10 mM; Novartis; all in ethanol), DAPT (5 mM; Sigma Aldrich; DMSO), and ROCK inhibitor (25 mM; Sigma Aldrich; DMSO).</p></sec></sec><sec sec-type="acknowledgement" id="sec4"><title>Author Contributions</title><p>J.M. and P.K. conceived and designed the study; collected, analyzed, and interpreted data; and wrote the manuscript. K.S., P.W., J.L., and J.C.K. collected, analyzed, and interpreted data. R.V., M.V., and P.v.D. provided material. J.W. and O.B. interpreted data, provided financial support, and wrote the manuscript.</p></sec></body><back><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Bannwarth</surname><given-names>B.</given-names></name><name><surname>Netter</surname><given-names>P.</given-names></name><name><surname>Lapicque</surname><given-names>F.</given-names></name><name><surname>Péré</surname><given-names>P.</given-names></name><name><surname>Thomas</surname><given-names>P.</given-names></name><name><surname>Gaucher</surname><given-names>A.</given-names></name></person-group><article-title>Plasma and cerebrospinal fluid concentrations of indomethacin in humans. Relationship to analgesic activity</article-title><source>Eur. J. Clin. Pharmacol.</source><volume>38</volume><year>1990</year><fpage>343</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">2344858</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K.</given-names></name><name><surname>Zetterberg</surname><given-names>H.</given-names></name><name><surname>Fagan</surname><given-names>A.M.</given-names></name></person-group><article-title>Fluid biomarkers in Alzheimer disease</article-title><source>Cold Spring Harb Perspect Med</source><volume>2</volume><year>2012</year></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Borchelt</surname><given-names>D.R.</given-names></name><name><surname>Thinakaran</surname><given-names>G.</given-names></name><name><surname>Eckman</surname><given-names>C.B.</given-names></name><name><surname>Lee</surname><given-names>M.K.</given-names></name><name><surname>Davenport</surname><given-names>F.</given-names></name><name><surname>Ratovitsky</surname><given-names>T.</given-names></name><name><surname>Prada</surname><given-names>C.M.</given-names></name><name><surname>Kim</surname><given-names>G.</given-names></name><name><surname>Seekins</surname><given-names>S.</given-names></name><name><surname>Yager</surname><given-names>D.</given-names></name></person-group><article-title>Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo</article-title><source>Neuron</source><volume>17</volume><year>1996</year><fpage>1005</fpage><lpage>1013</lpage><pub-id pub-id-type="pmid">8938131</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Citron</surname><given-names>M.</given-names></name><name><surname>Oltersdorf</surname><given-names>T.</given-names></name><name><surname>Haass</surname><given-names>C.</given-names></name><name><surname>McConlogue</surname><given-names>L.</given-names></name><name><surname>Hung</surname><given-names>A.Y.</given-names></name><name><surname>Seubert</surname><given-names>P.</given-names></name><name><surname>Vigo-Pelfrey</surname><given-names>C.</given-names></name><name><surname>Lieberburg</surname><given-names>I.</given-names></name><name><surname>Selkoe</surname><given-names>D.J.</given-names></name></person-group><article-title>Mutation of the beta-amyloid precursor protein in familial Alzheimer’s disease increases beta-protein production</article-title><source>Nature</source><volume>360</volume><year>1992</year><fpage>672</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">1465129</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>D.</given-names></name><name><surname>Jansen</surname><given-names>R.</given-names></name><name><surname>Hoefnagels</surname><given-names>W.</given-names></name><name><surname>Jellesma-Eggenkamp</surname><given-names>M.</given-names></name><name><surname>Verbeek</surname><given-names>M.</given-names></name><name><surname>Borm</surname><given-names>G.</given-names></name><name><surname>Kremer</surname><given-names>B.</given-names></name></person-group><article-title>No effect of one-year treatment with indomethacin on Alzheimer’s disease progression: a randomized controlled trial</article-title><source>PLoS ONE</source><volume>3</volume><year>2008</year><fpage>e1475</fpage><pub-id pub-id-type="pmid">18213383</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Eriksen</surname><given-names>J.L.</given-names></name><name><surname>Sagi</surname><given-names>S.A.</given-names></name><name><surname>Smith</surname><given-names>T.E.</given-names></name><name><surname>Weggen</surname><given-names>S.</given-names></name><name><surname>Das</surname><given-names>P.</given-names></name><name><surname>McLendon</surname><given-names>D.C.</given-names></name><name><surname>Ozols</surname><given-names>V.V.</given-names></name><name><surname>Jessing</surname><given-names>K.W.</given-names></name><name><surname>Zavitz</surname><given-names>K.H.</given-names></name><name><surname>Koo</surname><given-names>E.H.</given-names></name><name><surname>Golde</surname><given-names>T.E.</given-names></name></person-group><article-title>NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo</article-title><source>J. Clin. Invest.</source><volume>112</volume><year>2003</year><fpage>440</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">12897211</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Falk</surname><given-names>A.</given-names></name><name><surname>Koch</surname><given-names>P.</given-names></name><name><surname>Kesavan</surname><given-names>J.</given-names></name><name><surname>Takashima</surname><given-names>Y.</given-names></name><name><surname>Ladewig</surname><given-names>J.</given-names></name><name><surname>Alexander</surname><given-names>M.</given-names></name><name><surname>Wiskow</surname><given-names>O.</given-names></name><name><surname>Tailor</surname><given-names>J.</given-names></name><name><surname>Trotter</surname><given-names>M.</given-names></name><name><surname>Pollard</surname><given-names>S.</given-names></name></person-group><article-title>Capture of neuroepithelial-like stem cells from pluripotent stem cells provides a versatile system for in vitro production of human neurons</article-title><source>PLoS ONE</source><volume>7</volume><year>2012</year><fpage>e29597</fpage><pub-id pub-id-type="pmid">22272239</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Galasko</surname><given-names>D.R.</given-names></name><name><surname>Graff-Radford</surname><given-names>N.</given-names></name><name><surname>May</surname><given-names>S.</given-names></name><name><surname>Hendrix</surname><given-names>S.</given-names></name><name><surname>Cottrell</surname><given-names>B.A.</given-names></name><name><surname>Sagi</surname><given-names>S.A.</given-names></name><name><surname>Mather</surname><given-names>G.</given-names></name><name><surname>Laughlin</surname><given-names>M.</given-names></name><name><surname>Zavitz</surname><given-names>K.H.</given-names></name><name><surname>Swabb</surname><given-names>E.</given-names></name></person-group><article-title>Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals</article-title><source>Alzheimer Dis. Assoc. Disord.</source><volume>21</volume><year>2007</year><fpage>292</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">18090435</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>A.K.</given-names></name><name><surname>Brindisi</surname><given-names>M.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name></person-group><article-title>Developing β-secretase inhibitors for treatment of Alzheimer’s disease</article-title><source>J. Neurochem.</source><volume>120</volume><issue>Suppl 1</issue><year>2012</year><fpage>71</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">22122681</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Golde</surname><given-names>T.E.</given-names></name><name><surname>Schneider</surname><given-names>L.S.</given-names></name><name><surname>Koo</surname><given-names>E.H.</given-names></name></person-group><article-title>Anti-aβ therapeutics in Alzheimer’s disease: the need for a paradigm shift</article-title><source>Neuron</source><volume>69</volume><year>2011</year><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">21262461</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Green</surname><given-names>R.C.</given-names></name><name><surname>Schneider</surname><given-names>L.S.</given-names></name><name><surname>Amato</surname><given-names>D.A.</given-names></name><name><surname>Beelen</surname><given-names>A.P.</given-names></name><name><surname>Wilcock</surname><given-names>G.</given-names></name><name><surname>Swabb</surname><given-names>E.A.</given-names></name><name><surname>Zavitz</surname><given-names>K.H.</given-names></name><collab>Tarenflurbil Phase 3 Study Group.</collab></person-group><article-title>Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial</article-title><source>JAMA</source><volume>302</volume><year>2009</year><fpage>2557</fpage><lpage>2564</lpage><pub-id pub-id-type="pmid">20009055</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Haass</surname><given-names>C.</given-names></name><name><surname>Kaether</surname><given-names>C.</given-names></name><name><surname>Thinakaran</surname><given-names>G.</given-names></name><name><surname>Sisodia</surname><given-names>S.</given-names></name></person-group><article-title>Trafficking and proteolytic processing of APP</article-title><source>Cold Spring Harb. Perspect. Med.</source><volume>2</volume><year>2012</year><fpage>a006270</fpage><pub-id pub-id-type="pmid">22553493</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Imbimbo</surname><given-names>B.P.</given-names></name><name><surname>Giardina</surname><given-names>G.A.</given-names></name></person-group><article-title>γ-secretase inhibitors and modulators for the treatment of Alzheimer’s disease: disappointments and hopes</article-title><source>Curr. Top. Med. Chem.</source><volume>11</volume><year>2011</year><fpage>1555</fpage><lpage>1570</lpage><pub-id pub-id-type="pmid">21510832</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Israel</surname><given-names>M.A.</given-names></name><name><surname>Yuan</surname><given-names>S.H.</given-names></name><name><surname>Bardy</surname><given-names>C.</given-names></name><name><surname>Reyna</surname><given-names>S.M.</given-names></name><name><surname>Mu</surname><given-names>Y.</given-names></name><name><surname>Herrera</surname><given-names>C.</given-names></name><name><surname>Hefferan</surname><given-names>M.P.</given-names></name><name><surname>Van Gorp</surname><given-names>S.</given-names></name><name><surname>Nazor</surname><given-names>K.L.</given-names></name><name><surname>Boscolo</surname><given-names>F.S.</given-names></name></person-group><article-title>Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells</article-title><source>Nature</source><volume>482</volume><year>2012</year><fpage>216</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">22278060</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Jumpertz</surname><given-names>T.</given-names></name><name><surname>Rennhack</surname><given-names>A.</given-names></name><name><surname>Ness</surname><given-names>J.</given-names></name><name><surname>Baches</surname><given-names>S.</given-names></name><name><surname>Pietrzik</surname><given-names>C.U.</given-names></name><name><surname>Bulic</surname><given-names>B.</given-names></name><name><surname>Weggen</surname><given-names>S.</given-names></name></person-group><article-title>Presenilin is the molecular target of acidic γ-secretase modulators in living cells</article-title><source>PLoS ONE</source><volume>7</volume><year>2012</year><fpage>e30484</fpage><pub-id pub-id-type="pmid">22238696</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Karran</surname><given-names>E.</given-names></name><name><surname>Mercken</surname><given-names>M.</given-names></name><name><surname>De Strooper</surname><given-names>B.</given-names></name></person-group><article-title>The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics</article-title><source>Nat. Rev. Drug Discov.</source><volume>10</volume><year>2011</year><fpage>698</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">21852788</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>P.</given-names></name><name><surname>Opitz</surname><given-names>T.</given-names></name><name><surname>Steinbeck</surname><given-names>J.A.</given-names></name><name><surname>Ladewig</surname><given-names>J.</given-names></name><name><surname>Brüstle</surname><given-names>O.</given-names></name></person-group><article-title>A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>106</volume><year>2009</year><fpage>3225</fpage><lpage>3230</lpage><pub-id pub-id-type="pmid">19218428</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>P.</given-names></name><name><surname>Breuer</surname><given-names>P.</given-names></name><name><surname>Peitz</surname><given-names>M.</given-names></name><name><surname>Jungverdorben</surname><given-names>J.</given-names></name><name><surname>Kesavan</surname><given-names>J.</given-names></name><name><surname>Poppe</surname><given-names>D.</given-names></name><name><surname>Doerr</surname><given-names>J.</given-names></name><name><surname>Ladewig</surname><given-names>J.</given-names></name><name><surname>Mertens</surname><given-names>J.</given-names></name><name><surname>Tüting</surname><given-names>T.</given-names></name></person-group><article-title>Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease</article-title><source>Nature</source><volume>480</volume><year>2011</year><fpage>543</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">22113611</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>P.</given-names></name><name><surname>Tamboli</surname><given-names>I.Y.</given-names></name><name><surname>Mertens</surname><given-names>J.</given-names></name><name><surname>Wunderlich</surname><given-names>P.</given-names></name><name><surname>Ladewig</surname><given-names>J.</given-names></name><name><surname>Stüber</surname><given-names>K.</given-names></name><name><surname>Esselmann</surname><given-names>H.</given-names></name><name><surname>Wiltfang</surname><given-names>J.</given-names></name><name><surname>Brüstle</surname><given-names>O.</given-names></name><name><surname>Walter</surname><given-names>J.</given-names></name></person-group><article-title>Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of γ-secretase activity in endogenous amyloid-β generation</article-title><source>Am. J. Pathol.</source><volume>180</volume><year>2012</year><fpage>2404</fpage><lpage>2416</lpage><pub-id pub-id-type="pmid">22510327</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Kukar</surname><given-names>T.L.</given-names></name><name><surname>Ladd</surname><given-names>T.B.</given-names></name><name><surname>Bann</surname><given-names>M.A.</given-names></name><name><surname>Fraering</surname><given-names>P.C.</given-names></name><name><surname>Narlawar</surname><given-names>R.</given-names></name><name><surname>Maharvi</surname><given-names>G.M.</given-names></name><name><surname>Healy</surname><given-names>B.</given-names></name><name><surname>Chapman</surname><given-names>R.</given-names></name><name><surname>Welzel</surname><given-names>A.T.</given-names></name><name><surname>Price</surname><given-names>R.W.</given-names></name></person-group><article-title>Substrate-targeting γ-secretase modulators</article-title><source>Nature</source><volume>453</volume><year>2008</year><fpage>925</fpage><lpage>929</lpage><pub-id pub-id-type="pmid">18548070</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Kumar-Singh</surname><given-names>S.</given-names></name><name><surname>Theuns</surname><given-names>J.</given-names></name><name><surname>Van Broeck</surname><given-names>B.</given-names></name><name><surname>Pirici</surname><given-names>D.</given-names></name><name><surname>Vennekens</surname><given-names>K.</given-names></name><name><surname>Corsmit</surname><given-names>E.</given-names></name><name><surname>Cruts</surname><given-names>M.</given-names></name><name><surname>Dermaut</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C.</given-names></name></person-group><article-title>Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40</article-title><source>Hum. Mutat.</source><volume>27</volume><year>2006</year><fpage>686</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">16752394</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Kumpulainen</surname><given-names>E.</given-names></name><name><surname>Välitalo</surname><given-names>P.</given-names></name><name><surname>Kokki</surname><given-names>M.</given-names></name><name><surname>Lehtonen</surname><given-names>M.</given-names></name><name><surname>Hooker</surname><given-names>A.</given-names></name><name><surname>Ranta</surname><given-names>V.P.</given-names></name><name><surname>Kokki</surname><given-names>H.</given-names></name></person-group><article-title>Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children</article-title><source>Br. J. Clin. Pharmacol.</source><volume>70</volume><year>2010</year><fpage>557</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">20840447</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Larner</surname><given-names>A.J.</given-names></name><name><surname>Doran</surname><given-names>M.</given-names></name></person-group><article-title>Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1 gene</article-title><source>J. Neurol.</source><volume>253</volume><year>2006</year><fpage>139</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">16267640</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Mattis</surname><given-names>V.B.</given-names></name><name><surname>Svendsen</surname><given-names>C.N.</given-names></name></person-group><article-title>Induced pluripotent stem cells: a new revolution for clinical neurology?</article-title><source>Lancet Neurol.</source><volume>10</volume><year>2011</year><fpage>383</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">21435601</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Mertens</surname><given-names>J.</given-names></name><name><surname>Stüber</surname><given-names>K.</given-names></name><name><surname>Poppe</surname><given-names>D.</given-names></name><name><surname>Doerr</surname><given-names>J.</given-names></name><name><surname>Ladewig</surname><given-names>J.</given-names></name><name><surname>Brüstle</surname><given-names>O.</given-names></name><name><surname>Koch</surname><given-names>P.</given-names></name></person-group><article-title>Embryonic stem cell-based modeling of tau pathology in human neurons</article-title><source>Am. J. Pathol.</source><volume>182</volume><year>2013</year><fpage>1769</fpage><lpage>1779</lpage><pub-id pub-id-type="pmid">23499461</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Rajendran</surname><given-names>L.</given-names></name><name><surname>Knölker</surname><given-names>H.J.</given-names></name><name><surname>Simons</surname><given-names>K.</given-names></name></person-group><article-title>Subcellular targeting strategies for drug design and delivery</article-title><source>Nat. Rev. Drug Discov.</source><volume>9</volume><year>2010</year><fpage>29</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">20043027</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="book" id="sref27"><person-group person-group-type="author"><name><surname>Ritschel</surname><given-names>W.A.</given-names></name></person-group><chapter-title>Handbook of Basic Pharmacokinetics—Including Clinical Applications</chapter-title><year>1999</year><publisher-name>American Pharmaceutical Association</publisher-name><publisher-loc>Washington, DC</publisher-loc></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Selkoe</surname><given-names>D.J.</given-names></name></person-group><article-title>Alzheimer’s disease: genes, proteins, and therapy</article-title><source>Physiol. Rev.</source><volume>81</volume><year>2001</year><fpage>741</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">11274343</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Selkoe</surname><given-names>D.</given-names></name><name><surname>Mandelkow</surname><given-names>E.</given-names></name><name><surname>Holtzman</surname><given-names>D.</given-names></name></person-group><article-title>Deciphering Alzheimer disease</article-title><source>Cold Spring Harb. Perspect. Med.</source><volume>2</volume><year>2012</year><fpage>a011460</fpage><pub-id pub-id-type="pmid">22315723</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K.</given-names></name><name><surname>Tanabe</surname><given-names>K.</given-names></name><name><surname>Ohnuki</surname><given-names>M.</given-names></name><name><surname>Narita</surname><given-names>M.</given-names></name><name><surname>Ichisaka</surname><given-names>T.</given-names></name><name><surname>Tomoda</surname><given-names>K.</given-names></name><name><surname>Yamanaka</surname><given-names>S.</given-names></name></person-group><article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title><source>Cell</source><volume>131</volume><year>2007</year><fpage>861</fpage><lpage>872</lpage><pub-id pub-id-type="pmid">18035408</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Theuns</surname><given-names>J.</given-names></name><name><surname>Marjaux</surname><given-names>E.</given-names></name><name><surname>Vandenbulcke</surname><given-names>M.</given-names></name><name><surname>Van Laere</surname><given-names>K.</given-names></name><name><surname>Kumar-Singh</surname><given-names>S.</given-names></name><name><surname>Bormans</surname><given-names>G.</given-names></name><name><surname>Brouwers</surname><given-names>N.</given-names></name><name><surname>Van den Broeck</surname><given-names>M.</given-names></name><name><surname>Vennekens</surname><given-names>K.</given-names></name><name><surname>Corsmit</surname><given-names>E.</given-names></name></person-group><article-title>Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment</article-title><source>Hum. Mutat.</source><volume>27</volume><year>2006</year><fpage>888</fpage><lpage>896</lpage><pub-id pub-id-type="pmid">16917905</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Vellas</surname><given-names>B.</given-names></name></person-group><article-title>Tarenflurbil for Alzheimer’s disease: a “shot on goal” that missed</article-title><source>Lancet Neurol.</source><volume>9</volume><year>2010</year><fpage>235</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">20170836</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Weggen</surname><given-names>S.</given-names></name><name><surname>Eriksen</surname><given-names>J.L.</given-names></name><name><surname>Das</surname><given-names>P.</given-names></name><name><surname>Sagi</surname><given-names>S.A.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Pietrzik</surname><given-names>C.U.</given-names></name><name><surname>Findlay</surname><given-names>K.A.</given-names></name><name><surname>Smith</surname><given-names>T.E.</given-names></name><name><surname>Murphy</surname><given-names>M.P.</given-names></name><name><surname>Bulter</surname><given-names>T.</given-names></name></person-group><article-title>A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity</article-title><source>Nature</source><volume>414</volume><year>2001</year><fpage>212</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">11700559</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Wiltfang</surname><given-names>J.</given-names></name><name><surname>Esselmann</surname><given-names>H.</given-names></name><name><surname>Cupers</surname><given-names>P.</given-names></name><name><surname>Neumann</surname><given-names>M.</given-names></name><name><surname>Kretzschmar</surname><given-names>H.</given-names></name><name><surname>Beyermann</surname><given-names>M.</given-names></name><name><surname>Schleuder</surname><given-names>D.</given-names></name><name><surname>Jahn</surname><given-names>H.</given-names></name><name><surname>Rüther</surname><given-names>E.</given-names></name><name><surname>Kornhuber</surname><given-names>J.</given-names></name></person-group><article-title>Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer’s disease and its generation in PS1 knockout cells</article-title><source>J. Biol. Chem.</source><volume>276</volume><year>2001</year><fpage>42645</fpage><lpage>42657</lpage><pub-id pub-id-type="pmid">11526104</pub-id></element-citation></ref></ref-list><sec id="app2" sec-type="supplementary-material"><title>Supplemental Information</title><p><supplementary-material content-type="local-data" id="mmc1"><caption><title>Document S1. Supplemental Experimental Procedures, Figures S1–S3, and Table S1</title></caption><media xlink:href="mmc1.pdf"></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p>We thank Dr. Peter Davies for the PHF1 antibody, Dr. Harald Steiner for HEK<sub>swe</sub> cells, and Svenja Auel for technical support. The human hESC-derived lt-NES cell lines were previously generated from the hESC lines I3 (hES-1) and I6 (hES-2), which were originally provided by Joseph Itskovitz-Eldor (Technion, Israel Institute of Technology, Haifa, Israel). This work was supported by the German Federal Ministry for Education and Research (BMBF; BioPharma-NeuroAllianz grants 1615608A and 1615608B), the SCR&Tox consortium under the FP7-HEALTH-2010-Alternative-Testing-Strategies of the European Union (project No. 266753), the DFG (KFO177, WA1477/6, and SFB 645), the Hertie Foundation, and the Glenn Center for Aging Research.</p></ack><fn-group><fn id="d32e124"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.</p></fn></fn-group></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Human Neural Stem Cells and Neurons from Ctrl and AD-Patient-Specific iPSCs</p><p>(A) Experimental design: iPSCs were generated from dermal fibroblasts (<xref rid="bib30" ref-type="bibr">Takahashi et al., 2007</xref>) and differentiated into lt-NES cell lines (n = 11 [5 Ctrl-iPSC derived, 4 AD-iPSC derived, and 2 hESC derived]). Lt-NES cells were differentiated for 4 weeks into mature neuronal cultures and subjected to GSM treatment and Aβ ELISA measurements in the conditioned media.</p><p>(B) Immunocytochemical characterization of lt-NES cells and differentiated neuronal cultures. Lt-NES were stained for the neuroectodermal stem cell markers Nestin, PLZF, DACH1, SOX2, and ZO-1. Differentiated cultures were analyzed for expression of β-III tubulin, GFAP, MAP2ab, phosphorylated Tau (PHF1), PS1, and APP. Scale bars, 20 μm.</p><p>(C) Electrophysiological characterization of AD neurons. Representative traces depict multiple evoked action potentials during current-clamp recording (n = 6) as well as whole-cell currents showing TTx/Cd<sup>2+</sup>-sensitive Na<sup>+</sup> channel-mediated inward currents and 4-AP-sensitive K<sup>+</sup> channel-mediated outward currents in response to depolarizing voltage steps (n = 7). Spontaneous postsynaptic currents in neurons demonstrate functional synapses (n = 6).</p><p>See also <xref rid="app2" ref-type="sec">Figure S1</xref>.</p></caption><graphic xlink:href="gr1"></graphic></fig><fig id="fig2"><label>Figure 2</label><caption><p>AD Patient iPSC-Derived Neurons Show Elevated Aβ42/Aβ40 Ratios that Can Be Lowered by High Concentrations of NSAID-Based GSMs</p><p>(A) Endogenous secretion of Aβ40 and Aβ42 was analyzed by ELISA in conditioned media of differentiated neuronal cultures, and Aβ42/Aß40 ratios were calculated.</p><p>(B) The total levels of Aβ40 and Aβ42 were measured and normalized to the total cellular protein amount of the respective cultures.</p><p>(C) High-concentration screen: Aβ42/Aß40 ratios of differentiated neuronal cultures treated for 36 hr with 200 μM indometacin, ibuprofen, diclofenac, or flurbiprofen. Bar graphs show mean + SD; significance values determined by ANOVA: <sup>∗</sup>p ≤ 0.01; <sup>∗∗</sup>p ≤ 0.001.</p><p>ELISA measurements were performed at least as biological triplicates.</p><p>See also <xref rid="app2" ref-type="sec">Figure S2</xref>.</p></caption><graphic xlink:href="gr2"></graphic></fig><fig id="fig3"><label>Figure 3</label><caption><p>Human Neurons from Ctrl- and AD-Patient-Derived iPSCs Are Resistant to Therapeutically Relevant Concentrations of NSAID-Based GSMs that Failed in Clinical Trials</p><p>(A) Effect on the Aβ42/Aß40 ratio of GSM concentrations that can be reached in the human CSF (<xref rid="bib1 bib22 bib27" ref-type="bibr">Bannwarth et al., 1990; Kumpulainen et al., 2010; Ritschel, 1999</xref>). Ctrl and AD neurons, as well as CHO-APP<sub>695</sub>, CHO-APP<sub>SWE</sub>, and HEK-APP<sub>SWE</sub> cells, were treated with increasing concentrations of indometacin and Aβ42/Aß40 ratios were measured.</p><p>(B) Total Aβ40 and Aβ42 levels in conditioned media of human neurons (Ctrl-1) and HEK-APP<sub>SWE</sub> and CHO-APP<sub>695</sub> cells treated with different concentrations of indometacin.</p><p>(C) Aβ42/Aß40 ratios in human neurons (Ctrl-2) and HEK-APP<sub>SWE</sub> and CHO-APP<sub>695</sub> cells in response to flurbiprofen. Data in (A)–(C) are depicted as mean ± SEM.</p><p>(D) Aβ42/Aß40 ratios of APP<sub>695</sub>-overexpressing hESC-derived neurons treated with flurbiprofen. All ELISA measurements were performed at least as biological triplicates. Bar graph shows mean + SD. Significance values determined by ANOVA: <sup>∗</sup>p ≤ 0.01; <sup>∗∗</sup>p ≤ 0.001.</p><p>See also <xref rid="app2" ref-type="sec">Figure S3</xref>.</p></caption><graphic xlink:href="gr3"></graphic></fig></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000260 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000260 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:3871388
|texte= APP Processing in Human Pluripotent Stem Cell-Derived Neurons Is Resistant to NSAID-Based γ-Secretase Modulation
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:24371804" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a OpenAccessBelV2
| This area was generated with Dilib version V0.6.25. |  |